Literature DB >> 32366462

Malaria parasite plasmepsins: More than just plain old degradative pepsins.

Armiyaw S Nasamu1, Alexander J Polino1, Eva S Istvan1, Daniel E Goldberg2.   

Abstract

Plasmepsins are a group of diverse aspartic proteases in the malaria parasite Plasmodium Their functions are strikingly multifaceted, ranging from hemoglobin degradation to secretory organelle protein processing for egress, invasion, and effector export. Some, particularly the digestive vacuole plasmepsins, have been extensively characterized, whereas others, such as the transmission-stage plasmepsins, are minimally understood. Some (e.g. plasmepsin V) have exquisite cleavage sequence specificity; others are fairly promiscuous. Some have canonical pepsin-like aspartic protease features, whereas others have unusual attributes, including the nepenthesin loop of plasmepsin V and a histidine in place of a catalytic aspartate in plasmepsin III. We have learned much about the functioning of these enzymes, but more remains to be discovered about their cellular roles and even their mechanisms of action. Their importance in many key aspects of parasite biology makes them intriguing targets for antimalarial chemotherapy. Further consideration of their characteristics suggests that some are more viable drug targets than others. Indeed, inhibitors of invasion and egress offer hope for a desperately needed new drug to combat this nefarious organism.
© 2020 Nasamu et al.

Entities:  

Keywords:  antimalarial chemotherapy; aspartic protease; digestive vacuole; hemoglobin; malaria; maturase; parasitology; plasmodium; protease; protozoan; transmission

Mesh:

Substances:

Year:  2020        PMID: 32366462      PMCID: PMC7307202          DOI: 10.1074/jbc.REV120.009309

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  185 in total

1.  Inhibition of Plasmepsin V Activity Blocks Plasmodium falciparum Gametocytogenesis and Transmission to Mosquitoes.

Authors:  Charlie Jennison; Leonardo Lucantoni; Matthew T O'Neill; Robyn McConville; Sara M Erickson; Alan F Cowman; Brad E Sleebs; Vicky M Avery; Justin A Boddey
Journal:  Cell Rep       Date:  2019-12-17       Impact factor: 9.423

2.  Plasmodium falciparum: isolation and characterization of a 55-kDa protease with a cathepsin D-like activity from P. falciparum.

Authors:  E Bailly; J Savel; G Mahouy; G Jaureguiberry
Journal:  Exp Parasitol       Date:  1991-04       Impact factor: 2.011

3.  Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.

Authors:  Sunil Parikh; Jiri Gut; Eva Istvan; Daniel E Goldberg; Diane V Havlir; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

4.  Plasmepsin 4-deficient Plasmodium berghei are virulence attenuated and induce protective immunity against experimental malaria.

Authors:  Roberta Spaccapelo; Chris J Janse; Sara Caterbi; Blandine Franke-Fayard; J Alfredo Bonilla; Luke M Syphard; Manlio Di Cristina; Tania Dottorini; Andrea Savarino; Antonio Cassone; Francesco Bistoni; Andrew P Waters; John B Dame; Andrea Crisanti
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

5.  Crystal structure of the novel aspartic proteinase zymogen proplasmepsin II from plasmodium falciparum.

Authors:  N K Bernstein; M M Cherney; H Loetscher; R G Ridley; M N James
Journal:  Nat Struct Biol       Date:  1999-01

6.  Structural basis for plasmepsin V inhibition that blocks export of malaria proteins to human erythrocytes.

Authors:  Anthony N Hodder; Brad E Sleebs; Peter E Czabotar; Michelle Gazdik; Yibin Xu; Matthew T O'Neill; Sash Lopaticki; Thomas Nebl; Tony Triglia; Brian J Smith; Kym Lowes; Justin A Boddey; Alan F Cowman
Journal:  Nat Struct Mol Biol       Date:  2015-07-27       Impact factor: 15.369

7.  Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease.

Authors:  D E Goldberg; A F Slater; R Beavis; B Chait; A Cerami; G B Henderson
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

8.  Replication of Plasmodium in reticulocytes can occur without hemozoin formation, resulting in chloroquine resistance.

Authors:  Jing-Wen Lin; Roberta Spaccapelo; Evelin Schwarzer; Mohammed Sajid; Takeshi Annoura; Katrien Deroost; Raimond B G Ravelli; Elena Aime; Barbara Capuccini; Anna M Mommaas-Kienhuis; Tom O'Toole; Frans Prins; Blandine M D Franke-Fayard; Jai Ramesar; Séverine Chevalley-Maurel; Hans Kroeze; Abraham J Koster; Hans J Tanke; Andrea Crisanti; Jean Langhorne; Paolo Arese; Philippe E Van den Steen; Chris J Janse; Shahid M Khan
Journal:  J Exp Med       Date:  2015-05-04       Impact factor: 14.307

9.  Metabolic QTL analysis links chloroquine resistance in Plasmodium falciparum to impaired hemoglobin catabolism.

Authors:  Ian A Lewis; Mark Wacker; Kellen L Olszewski; Simon A Cobbold; Katelynn S Baska; Asako Tan; Michael T Ferdig; Manuel Llinás
Journal:  PLoS Genet       Date:  2014-01-02       Impact factor: 5.917

10.  Plasmodium falciparum ookinete expression of plasmepsin VII and plasmepsin X.

Authors:  Fengwu Li; Viengngeun Bounkeua; Kenneth Pettersen; Joseph M Vinetz
Journal:  Malar J       Date:  2016-02-24       Impact factor: 2.979

View more
  9 in total

1.  Artemisinin-Based Drugs Target the Plasmodium falciparum Heme Detoxification Pathway.

Authors:  Kaleab A Ribbiso; Laura E Heller; Abigail Taye; Erin Julian; Andreas V Willems; Paul D Roepe
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

Review 2.  How has mass drug administration with dihydroartemisinin-piperaquine impacted molecular markers of drug resistance? A systematic review.

Authors:  Susana Campino; Taane G Clark; Anna Last; Sophie Moss; Emilia Mańko; Sanjeev Krishna
Journal:  Malar J       Date:  2022-06-11       Impact factor: 3.469

Review 3.  A target safety assessment of the potential toxicological risks of targeting plasmepsin IX/X for the treatment of malaria.

Authors:  Jane Barber; Phumzile Sikakana; Claire Sadler; Delphine Baud; Jean-Pierre Valentin; Ruth Roberts
Journal:  Toxicol Res (Camb)       Date:  2021-02-15       Impact factor: 3.524

4.  Potential repurposing of four FDA approved compounds with antiplasmodial activity identified through proteome scale computational drug discovery and in vitro assay.

Authors:  Bakary N'tji Diallo; Tarryn Swart; Heinrich C Hoppe; Özlem Tastan Bishop; Kevin Lobb
Journal:  Sci Rep       Date:  2021-01-14       Impact factor: 4.379

Review 5.  Targeting the Plasmodium falciparum proteome and organelles for potential antimalarial drug candidates.

Authors:  James Abugri; Joseph Ayariga; Samuel Sunyazi Sunwiale; Cletus Adiyaga Wezena; Julien Agyemang Gyamfi; Michael Adu-Frimpong; Godfred Agongo; Julius Tieroyaare Dongdem; Daniel Abugri; Bismarck Dinko
Journal:  Heliyon       Date:  2022-08-24

6.  Babesia, Theileria, Plasmodium and Hemoglobin.

Authors:  Daniel Sojka; Marie Jalovecká; Jan Perner
Journal:  Microorganisms       Date:  2022-08-15

7.  Ellagic Acid Induces in vitro Alkalinisation of the Digestive Vacuole in Drug-Sensitive Plasmodium falciparum Strain.

Authors:  Nur Hazirah Muchtar; Nik Nor Imam Nik Mat Zin; Fatin Sofia Mohamad; Nurhidanatasha Abu-Bakar
Journal:  Malays J Med Sci       Date:  2022-08-29

Review 8.  Protease Inhibition-An Established Strategy to Combat Infectious Diseases.

Authors:  Daniel Sojka; Pavla Šnebergerová; Luïse Robbertse
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

Review 9.  The Role of the Iron Protoporphyrins Heme and Hematin in the Antimalarial Activity of Endoperoxide Drugs.

Authors:  Helenita C Quadros; Mariana C B Silva; Diogo R M Moreira
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.